Generic Name and Formulations:
Cevimeline HCl 30mg; caps.
Indications for EVOXAC:
Dry mouth associated with Sjogren's syndrome.
30mg three times daily.
Uncontrolled asthma. When miosis is undesirable (eg, acute iritis, narrow-angle glaucoma).
History of cardiovascular disease. Controlled asthma. Chronic bronchitis. COPD. History of nephrolithiasis or cholelithiasis. CYP2D6 deficiency. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiated by CYP2D6 and CYP3A3/4 inhibitors. Possible conduction disturbances with β-adrenergic antagonists. Additive effects with parasympathomimetics. May interfere with antimuscarinics.
Excessive sweating (dehydration may develop; drink extra water), rhinitis, excessive salivation, UTI, cough, arthralgia, fatigue, insomnia, hot flushes, GI upset, visual disturbances (eg, blurring, decreased visual acuity), others.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Risk of Developing Multiple Sclerosis After HPV Vaccination
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid-Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics